Jocelyn Dupuis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3924525/publications.pdf

Version: 2024-02-01

144 papers	9,137 citations	87888 38 h-index	40979 93 g-index
159 all docs	159 docs citations	159 times ranked	8825 citing authors

#	Article	IF	Citations
1	Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure. ESC Heart Failure, 2022, 9, 450-464.	3.1	16
2	Calcium Sensing Receptor Variants Increase Pulmonary Hypertension Susceptibility. Hypertension, 2022, 79, 1348-1360.	2.7	4
3	Long-Chain Acylcarnitines and Monounsaturated Fatty Acids Discriminate Heart Failure Patients According to Pulmonary Hypertension Status. Metabolites, 2021, 11, 196.	2.9	5
4	Dietary Geranylgeranyl Pyrophosphate Counteracts the Benefits of Statin Therapy in Experimental Pulmonary Hypertension. Circulation, 2021, 143, 1775-1792.	1.6	15
5	Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respiratory Medicine,the, 2021, 9, 924-932.	10.7	218
6	SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer. Respiratory Research, 2021, 22, 240.	3.6	0
7	Peptide Blocking Self-Polymerization of Extracellular Calcium-Sensing Receptor Attenuates Hypoxia-Induced Pulmonary Hypertension. Hypertension, 2021, 78, 1605-1616.	2.7	5
8	PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure. Cardiovascular Research, 2020, 116, 171-182.	3.8	14
9	Phenylalanine induces pulmonary hypertension through calcium-sensing receptor activation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L1010-L1020.	2.9	18
10	A Novel Molecular Pathway of Plaque Vulnerability Reveals a Cholesterol-Independent Effect of Statins and Supports Inflammation as a Therapeutic Target. Canadian Journal of Cardiology, 2020, 36, 1710-1713.	1.7	1
11	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. PLoS ONE, 2020, 15, e0242318.	2.5	28
12	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
13	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
14	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
15	Colchicine reduces lung injury in experimental acute respiratory distress syndrome. , 2020, 15, e0242318.		0
16	A webâ€based tailored nursing intervention (TAVIE en m@rche) aimed at increasing walking after an acute coronary syndrome: Multicentre randomized trial. Journal of Advanced Nursing, 2019, 75, 2727-2741.	3.3	4
17	Spermine on Endothelial Extracellular Vesicles Mediates Smoking-Induced Pulmonary Hypertension Partially Through Calcium-Sensing Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 482-495.	2.4	29
18	Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease. Circulation Research, 2019, 125, 449-466.	4.5	73

#	Article	IF	Citations
19	PulmoBind Imaging Measures Reduction of Vascular Adrenomedullin Receptor Activity with Lack of effect of Sildenafil in Pulmonary Hypertension. Scientific Reports, 2019, 9, 6609.	3.3	11
20	Secular Trends and Outcome of Isolated versus Combined Type 2 Pulmonary Hypertension in Patients with End-Stage Heart Failure. Journal of Heart and Lung Transplantation, 2019, 38, S486-S487.	0.6	0
21	Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L798-L809.	2.9	8
22	Sex- and Gender-Related Factors Associated With Cardiac Rehabilitation Enrollment. Journal of Cardiopulmonary Rehabilitation and Prevention, 2019, 39, 259-265.	2.1	15
23	Late Breaking Abstract - Inflammation and metabolic syndrome exacerbate pulmonary hypertension associated with left heart disease. , 2019, , .		0
24	SPECT and PET imaging of adrenomedullin receptors: a promising strategy for studying pulmonary vascular diseases. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 203-215.	1.0	2
25	A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors. American Journal of Pathology, 2018, 188, 1132-1148.	3.8	102
26	Echocardiographic validation of pulmonary hypertension due to heart failure with reduced ejection fraction in mice. Scientific Reports, 2018, 8, 1363.	3.3	14
27	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. Canadian Journal of Cardiology, 2018, 34, 214-233.	1.7	181
28	Impact of Pituitaryâ€“Gonadal Axis Hormones on Pulmonary Arterial Hypertension in Men. Hypertension, 2018, 72, 151-158.	2.7	25
29	Al[18F]F-complexation of DFH17, a NOTA-conjugated adrenomedullin analog, for PET imaging of pulmonary circulation. Nuclear Medicine and Biology, 2018, 67, 36-42.	0.6	11
30	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBIâ€“Cardiovascular Medical Research and Education Fund Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1661-1670.	5.6	59
31	Positive and Negative Affect Is Related to Experiencing Chest Pain During Exercise-Induced Myocardial Ischemia. Psychosomatic Medicine, 2017, 79, 395-403.	2.0	4
32	Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1136-1144.	6.4	11
33	Evaluation of a Web-Based Tailored Nursing Intervention (TAVIE en m@rche) Aimed at Increasing Walking After an Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial Protocol. JMIR Research Protocols, 2017, 6, e64.	1.0	3
34	A Web-Based Tailored Intervention to Support Illness Management in Patients With an Acute Coronary Syndrome: Pilot Study. JMIR Cardio, 2017, 1, e4.	1.7	1
35	Endothelial and Epithelial Cell Transition to a Mesenchymal Phenotype Was Delineated by Nestin Expression. Journal of Cellular Physiology, 2016, 231, 1601-1610.	4.1	9
36	Lung Capillary Stress Failure and Arteriolar Remodelling in Pulmonary Hypertension Associated with Left Heart Disease (Group 2 PH). Progress in Cardiovascular Diseases, 2016, 59, 11-21.	3.1	30

#	Article	IF	Citations
37	Evaluation of pulmonary perfusion by SPECT imaging using an endothelial cell tracer in supine humans and dogs. EJNMMI Research, 2016, 6, 43.	2.5	4
38	Molecular Imaging of the Human Pulmonary Vascular Endothelium Using an Adrenomedullin Receptor Ligand. Molecular Imaging, 2015, 14, 7290.2015.00003.	1.4	9
39	Relative associations between depression and anxiety on adverse cardiovascular events: does a history of coronary artery disease matter? A prospective observational study. BMJ Open, 2015, 5, e006582.	1.9	21
40	Nestin is a Marker of Lung Remodeling Secondary to Myocardial Infarction and Type I Diabetes in the Rat. Journal of Cellular Physiology, 2015, 230, 170-179.	4.1	19
41	Pathophysiology and Clinical Relevance of Pulmonary Remodelling in Pulmonary Hypertension due to Left Heart Diseases. Canadian Journal of Cardiology, 2015, 31, 416-429.	1.7	33
42	Expression of Phosphoinositide-Specific Phospholipase C Isoforms in Native Endothelial Cells. PLoS ONE, 2015, 10, e0123769.	2.5	16
43	Lung capillary injury and repair in left heart disease: a new target for therapy?. Clinical Science, 2014, 127, 65-76.	4.3	23
44	Molecular imaging of the pulmonary circulation in health and disease. Clinical and Translational Imaging, 2014, 2, 415-426.	2.1	8
45	Cardiopulmonary Bypass Is Associated With Altered Vascular Reactivity of Isolated Pulmonary Artery in a Porcine Model: Therapeutic Potential of Inhaled Tezosentan. Journal of Cardiothoracic and Vascular Anesthesia, 2014, 28, 698-708.	1.3	6
46	Pulmonary Production of Osteopontin in Humans: Effects of Left Ventricular Systolic Dysfunction and Cardiopulmonary Bypass. Journal of Cardiac Failure, 2013, 19, 816-820.	1.7	1
47	Cardiopulmonary Bypass Is Associated with Pulmonary Artery Endothelial Dysfunction: Therapeutic Potential of Tezosentan. Journal of Heart and Lung Transplantation, 2013, 32, S205.	0.6	0
48	Discovery of new antagonists aimed at discriminating <scp>UII</scp> and <scp>URP</scp>â€mediated biological activities: insight into <scp>UII</scp> and <scp>URP</scp> receptor activation. British Journal of Pharmacology, 2013, 168, 807-821.	5.4	31
49	PulmoBind, an Adrenomedullin-Based Molecular Lung Imaging Tool. Journal of Nuclear Medicine, 2013, 54, 1789-1796.	5.0	11
50	Randomized Controlled Trial of Tailored Nursing Interventions to Improve Cardiac Rehabilitation Enrollment. Nursing Research, 2012, 61, 111-120.	1.7	45
51	513 Elevated Osteopontin Levels in Patients With Chronic Heart Failure: Describing a Specific Physiopathologal Process. Canadian Journal of Cardiology, 2012, 28, S289.	1.7	1
52	Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. Biochemical Pharmacology, 2012, 83, 608-615.	4.4	25
53	Single measurement of troponin T for early prediction of infarct size, congestive heart failure, and pulmonary hypertension in an animal model of myocardial infarction. Cardiovascular Pathology, 2011, 20, e85-e89.	1.6	9
54	Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine. Nuclear Medicine and Biology, 2011, 38, 867-874.	0.6	5

#	Article	IF	Citations
55	Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure. BMC Cardiovascular Disorders, 2011, 11, 72.	1.7	8
56	The research on endothelial function in women and men at risk for cardiovascular disease (REWARD) study: methodology. BMC Cardiovascular Disorders, 2011, 11, 50.	1.7	20
57	Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. European Respiratory Journal, 2011, 37, 578-586.	6.7	22
58	Animal Models of Pulmonary Hypertension. , 2011, , 453-458.		1
59	Association Between Clinical Depression and Endothelial Function Measured by Forearm Hyperemic Reactivity. Psychosomatic Medicine, 2010, 72, 20-26.	2.0	63
60	Role Of Bosentan On Lung Structural Remodeling And Pulmonary Function In Ischemic Heart Failure. , 2010, , .		0
61	Characterization and reproducibility of forearm arterial flow during reactive hyperemia. Physiological Measurement, 2010, 31, 763-773.	2.1	6
62	Beneficial Effects of Atorvastatin on Lung Structural Remodeling and Function in Ischemic Heart Failure. Journal of Cardiac Failure, 2010, 16, 679-688.	1.7	20
63	Molecular Imaging of Monocrotaline-Induced Pulmonary Vascular Disease with Radiolabeled Linear Adrenomedullin. Journal of Nuclear Medicine, 2009, 50, 1110-1115.	5.0	11
64	Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging. European Journal of Pharmacology, 2009, 617, 118-123.	3.5	8
65	Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: Role of ETB-receptor expression levels. Pulmonary Pharmacology and Therapeutics, 2009, 22, 311-317.	2.6	34
66	Cellular and Molecular Basis of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2009, 54, S20-S31.	2.8	714
67	Downregulation of the Endothelin System of Lung Myofibroblasts in Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 2009, 54, 147-153.	1.9	1
68	Near-Infrared Spectroscopy to Monitor Peripheral Blood Flow Perfusion. Journal of Clinical Monitoring and Computing, 2008, 22, 37-43.	1.6	48
69	Endothelin-3-dependent pulmonary vasoconstriction in monocrotaline-induced pulmonary arterial hypertension. Peptides, 2008, 29, 2039-2045.	2.4	7
70	Role of endothelin receptors on basal and endothelin-1-stimulated lung myofibroblast proliferationThis article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in Endothelin.. Canadian Journal of Physiology and Pharmacology, 2008, 86, 337-342.	1.4	9
71	Endothelin receptor antagonists in pulmonary arterial hypertension. European Respiratory Journal, 2008, 31, 407-415.	6.7	185
72	Use of Adrenomedullin Derivatives for Molecular Imaging of Pulmonary Circulation. Journal of Nuclear Medicine, 2008, 49, 1869-1874.	5.0	13

#	Article	IF	Citations
73	Arterial flow measurements during reactive hyperemia using NIRS. Physiological Measurement, 2008, 29, 1033-1040.	2.1	13
74	Endothelin: setting the scene in PAH. European Respiratory Review, 2007, 16, 3-7.	7.1	18
75	Mobile detection system to evaluate reactive hyperemia using radionuclide plethysmography. Physiological Measurement, 2007, 28, 953-962.	2.1	2
76	Endothelin-1-Induced Pulmonary Vasoreactivity Is Regulated by ET_A and ET_B Receptor Interactions. Journal of Vascular Research, 2007, 44, 375-381.	1.4	57
77	Bone marrow-derived progenitor cells contribute to lung remodelling after myocardial infarction. Cardiovascular Pathology, 2007, 16, 321-328.	1.6	14
78	Demographics, treatment and outcome of acute coronary syndromes: 17 years of experience in a specialized cardiac centre. Canadian Journal of Cardiology, 2006, 22, 121-124.	1.7	12
79	Effects of Early Treatment With Statins on Short-term Clinical Outcomes in Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2006, 295, 2046.	7.4	146
80	Modification of the pulmonary reninâ€“angiotensin system and lung structural remodelling in congestive heart failure. Clinical Science, 2006, 111, 217-224.	4.3	22
81	Etiology-Specific Endothelin-1 Clearance in Human Precapillary Pulmonary Hypertension. Chest, 2006, 129, 689-695.	0.8	55
82	Effect of sternotomy and extracorporeal circulation on pulmonary neutrophil kinetics in pigs. Basic Research in Cardiology, 2006, 101, 133-139.	5.9	1
83	Short-Term Administration of a Cell-Permeable Caveolin-1 Peptide Prevents the Development of Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy. Circulation, 2006, 114, 912-920.	1.6	96
84	Effect of sternotomy and extracorporeal circulation on pulmonary neutrophil kinetics in pigs. FASEB Journal, 2006, 20, A282.	0.5	0
85	Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Experimental Biology and Medicine, 2006, 231, 840-6.	2.4	24
86	Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S.	0.8	23
87	Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin. Clinical Science, 2005, 109, 97-102.	4.3	37
88	Intensity of Lipid Lowering With Statins and Brachial Artery Vascular Endothelium Reactivity After Acute Coronary Syndromes (from the BRAVER Trial). American Journal of Cardiology, 2005, 96, 1207-1213.	1.6	39
89	Radionuclide plethysmography for noninvasive evaluation of peripheral arterial blood flow. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H258-H262.	3.2	16
90	Resident Nestin + Neural-Like Cells and Fibers Are Detected in Normal and Damaged Rat Myocardium. Hypertension, 2005, 46, 1219-1225.	2.7	54

#	Article	IF	Citations
91	Chronically Elevated Endothelin Levels Reduce Pulmonary Vascular Reactivity to Nitric Oxide. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 506-513.	5.6	31
92	A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study). American Heart Journal, 2005, 150, 933.e9-933.e13.	2.7	71
93	Noninvasive evaluation of endothelial vascular reactivity: should the quest continue?. Canadian Journal of Cardiology, 2005, 21, 1047-51.	1.7	2
94	Increased endothelin levels in congestive heart failure: does it come from the lungs? Does it matter?. Cardiovascular Research, 2004, 63, 5-7.	3.8	3
95	Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovascular Research, 2004, 63, 747-755.	3.8	79
96	Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imaging. Journal of the American College of Cardiology, 2004, 44, 1473-1477.	2.8	13
97	Reduced pulmonary clearance of endothelin in congestive heart failure: a marker of secondary pulmonary hypertension. Journal of Cardiac Failure, 2004, 10, 427-432.	1.7	33
98	Evaluation of Luminal Endothelin-Converting Enzyme Activity in the Pulmonary and Coronary Circulations. Journal of Cardiovascular Pharmacology, 2004, 43, 21-25.	1.9	4
99	Quantitative hyperemic reactivity in opposed limbs during myocardial perfusion imagingA new marker of coronary artery disease. Journal of the American College of Cardiology, 2004, 44, 1473-1477.	2.8	19
100	Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 642-649.	0.8	111
101	Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal of Medicine, 2003, 349, 1893-1906.	27.0	2,240
102	Absence of Association Between Infectious Agents and Endothelial Function in Healthy Young Men. Circulation, 2003, 107, 1966-1971.	1.6	56
103	The endothelin system in pulmonary hypertension. Canadian Journal of Physiology and Pharmacology, 2003, 81, 542-554.	1.4	51
104	Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovascular Research, 2003, 58, 621-631.	3.8	68
105	Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade. Clinical Science, 2003, 105, 647-653.	4.3	28
106	Reduction in hepatic endothelin-1 clearance in cirrhosis. Clinical Science, 2003, 105, 227-234.	4.3	17
107	Kinetic analysis of pulmonary neutrophil retention in vivo using the multiple-indicator-dilution technique. Journal of Applied Physiology, 2003, 95, 279-291.	2.5	11
108	In vivo measurement of coronary circulation angiotensin-converting enzyme activity in humans. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H17-H22.	3.2	5

#	Article	IF	Citations
109	Effect of ETAReceptor Antagonist on Pulmonary Hypertension and Vascular Reactivity in Rats With Congestive Heart Failure. Pulmonary Pharmacology and Therapeutics, 2001, 14, 307-314.	2.6	8
110	Mechanisms of acute coronary syndromes and the potential role of statins. Atherosclerosis Supplements, 2001, 2, 9-14.	1.2	21
111	Endothelin-receptor antagonists in pulmonary hypertension. Lancet, The, 2001, 358, 1113-1114.	13.7	50
112	Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. American Journal of Cardiology, 2001, 87, 375-380.	1.6	23
113	Pulmonary metabolism of endothelin 1 during on-pump and beating heart coronary artery bypass operations. Journal of Thoracic and Cardiovascular Surgery, 2001, 121, 1137-1142.	0.8	13
114	Intravascular Ultrasound Assessment of Pulmonary Vascular Disease in Patients With Pulmonary Hypertension. Chest, 2001, 120, 809-815.	0.8	43
115	Effectiveness of a Nonselective ETA/Band a Selective ETAAntagonist in Rats With Monocrotaline-Induced Pulmonary Hypertension. Circulation, 2001, 103, 314-318.	1.6	100
116	LU135252, an endothelinA receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. British Journal of Pharmacology, 2000, 130, 1525-1530.	5.4	29
117	Role of ET_A receptors in the regulation of vascular reactivity in rats with congestive heart failure. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 279, H844-H851.	3.2	13
118	Randomized Trial Comparing Intravenous Nitroglycerin and Heparin for Treatment of Unstable Angina Secondary to Restenosis After Coronary Artery Angioplasty. Circulation, 2000, 101, 955-961.	1.6	18
119	Importance of Local Production of Endothelin-1 and of the ETBReceptor in the Regulation of Pulmonary Vascular Tone. Pulmonary Pharmacology and Therapeutics, 2000, 13, 135-140.	2.6	54
120	Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. American Journal of Physiology - Renal Physiology, 1999, 277, G905-G914.	3.4	9
121	Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes. Circulation, 1999, 99, 3227-3233.	1.6	497
122	The ETA-Receptor Antagonist LU 135252 Prevents the Progression of Established Pulmonary Hypertension Induced by Monocrotaline in Rats. Journal of Cardiovascular Pharmacology and Therapeutics, 1999, 4, 33-39.	2.0	17
123	Comparison of nitroglycerin lingual spray and sublingual tablet on time of onset and duration of brachial artery vasodilation in normal subjects. American Journal of Cardiology, 1999, 84, 952-954.	1.6	60
124	Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. American Heart Journal, 1998, 135, 614-620.	2.7	91
125	Reduced Pulmonary Clearance of Endothelin-1 Contributes to the Increase of Circulating Levels in Heart Failure Secondary to Myocardial Infarction. Circulation, 1998, 98, 1684-1687.	1.6	59
126	Endothelin-1 Regulates Tone of Isolated Small Arteries in the Rat. Hypertension, 1998, 31, 1035-1041.	2.7	19

#	Article	IF	Citations
127	Endothelin _A Receptor Blockade Improves Nitric Oxideâ€“Mediated Vasodilation in Monocrotaline-Induced Pulmonary Hypertension. Circulation, 1998, 97, 2169-2174.	1.6	73
128	Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Cardiovascular Research, 1998, 39, 609-616.	3.8	21
129	Cholesterol Reduction Rapidly Improves Endothelial Function After Acute Coronary Syndromes. Journal of the American College of Cardiology, 1998, 31, 380A.	2.8	0
130	l-arginine prevents cyclosporin A-induced pulmonary vascular disfunction. Annals of Thoracic Surgery, 1997, 64, 414-420.	1.3	13
131	Endothelin-1 myocardial clearance, production, and effect on capillary permeability in vivo. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H1239-H1245.	3.2	5
132	Nitrates in Congestive Heart Failure. , 1997, , 191-203.		1
133	Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETBreceptors. Journal of the American College of Cardiology, 1996, 27, 104.	2.8	1
134	The pulmonary circulation is an important site for both clearance and production of endothelin-1 in humans. Journal of the American College of Cardiology, 1996, 27, 218.	2.8	0
135	Kinetics of pulmonary uptake of serotonin during exercise in dogs. Journal of Applied Physiology, 1996, 80, 30-46.	2.5	13
136	Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ET_Breceptors. Journal of Applied Physiology, 1996, 81, 1510-1515.	2.5	254
137	Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1. Circulation, 1996, 94, 1578-1584.	1.6	258
138	Pulmonary removal and production of endothelin in the anesthetized dog. Journal of Applied Physiology, 1994, 76, 694-700.	2.5	40
139	Nitrates in congestive heart failure. Cardiovascular Drugs and Therapy, 1994, 8, 501-507.	2.6	13
140	Paradoxical decrease in circulating neuropeptide Y-like immunoreactivity during mild orthostatic stress in subjects with and without congestive heart failure. European Heart Journal, 1993, 14, 34-39.	2.2	62
141	Pulmonary angiotensin-converting enzyme substrate hydrolysis during exercise. Journal of Applied Physiology, 1992, 72, 1868-1886.	2.5	27
142	Use of norepinephrine uptake to measure lung capillary recruitment with exercise. Journal of Applied Physiology, 1990, 68, 700-713.	2.5	20
143	Sustained beneficial effect of a seventy-two hour intravenous infusion of nitroglycerin in patients with severe chronic congestive heart failure. American Heart Journal, 1990, 120, 625-637.	2.7	38
144	Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. Journal of the American College of Cardiology, 1990, 16, 923-931.	2.8	200